IP
ACAD icon

Intellectus Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Intellectus Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200
Closed -$4K – 268
2018
Q3 		$4K Hold
200
– – ﹤0.01% 537
2018
Q2 		$3K Hold
200
– – ﹤0.01% 550
2018
Q1 		$4K Hold
200
– – ﹤0.01% 544
2017
Q4 		$6K Hold
200
– – ﹤0.01% 521
2017
Q3 		$8K Hold
200
– – ﹤0.01% 631
2017
Q2 		$6K Hold
200
– – ﹤0.01% 646
2017
Q1 		$7K Hold
200
– – ﹤0.01% 559
2016
Q4 		$6K Buy
+200
New +$5.29K ﹤0.01% 563

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Intellectus Partners's ACAD Position: Q4 2018 in Review

Intellectus Partners sold out of Acadia Pharmaceuticals (ACAD) in Q4 2018, closing a stake of 200 shares — an estimated $4K sold.

Intellectus Partners first reported a position in ACAD in Q4 2016 and held it in 8 quarters. The position peaked at $8K in Q3 2017. 186 funds tracked by Wall St. Rank hold ACAD as of Q4 2018.

  • Intellectus Partners reported no remaining Acadia Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 200 Acadia Pharmaceuticals shares in Q4 2018, an estimated $4K.
  • Intellectus Partners first reported a position in Acadia Pharmaceuticals in Q4 2016 and held it in 8 quarters.
  • Intellectus Partners's Acadia Pharmaceuticals position peaked at $8K in Q3 2017.
  • 186 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.